Sale disclosed
Michael J. Farrell
Chairman and CEO
ResMed Common Stock
- Reported value
- $1.11M
- Reported price
- $222.4385 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
RESMED INC
Last 30 daysNo qualifying insider buying. Sales: $1.11M by 1 insider.
Showing the first 6 of 10 trades on this page.
Chairman and CEO
ResMed Common Stock
Director
ResMed Common Stock
Chairman and CEO
ResMed Common Stock
Director
ResMed Common Stock
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock
Chief Financial Officer
ResMed Common Stock
Director
ResMed Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Chairman and CEO | ResMed Common StockSale10b5-1 | 4,991$222.44 / share | $1.11M | Sep 8Filed Sep 10 · 2d later | SEC filing |
| Director | ResMed Common StockSale10b5-1 | 970$234.73 / share | $227.69K | Sep 2Filed Sep 4 · 2d later | SEC filing |
| Chairman and CEO | ResMed Common StockSale10b5-1 | 4,991$205.69 / share | $1.03M | Aug 7Filed Aug 11 · 4d later | SEC filing |
| Director | ResMed Common StockSale10b5-1 | 8,000$225.00 / share | $1.8M | Aug 5Filed Aug 6 · 1d later | SEC filing |
| Chairman and CEO | ResMed Common StockSale10b5-1 | 4,991$218.55 / share | $1.09M | Jul 7Filed Jul 9 · 2d later | SEC filing |
| Chairman and CEO | ResMed Common StockSale10b5-1 | 4,991$193.96 / share | $968.06K | Jun 8Filed Jun 9 · 1d later | SEC filing |
| Chairman and CEO | ResMed Common StockSale10b5-1 | 4,991$207.82 / share | $1.04M | May 7Filed May 11 · 4d later | SEC filing |
| Chairman and CEO | ResMed Common StockSale10b5-1 | 4,991$225.50 / share | $1.13M | Apr 7Filed Apr 9 · 2d later | SEC filing |
| Chief Financial Officer | ResMed Common StockSale10b5-1 | 1,000$224.31 / share | $224.31K | Apr 1Filed Apr 3 · 2d later | SEC filing |
| Director | ResMed Common StockSale10b5-1 | 2,000$225.00 / share | $450K | Apr 1Filed Apr 2 · 1d later | SEC filing |
ResMed Inc. Common Stock · Stock
The filing reports a full sale for a joint account.
Thomas H TubervilleReporting Senate memberResMed Inc. Common Stock · Stock
The filing reports a purchase for the member.
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.